| scholarly article | Q13442814 |
| P50 | author | Jinqiang Zhang | Q83830610 |
| P2093 | author name string | Tong Wu | |
| Chang Han | |||
| P2860 | cites work | Identification of c-MYC as a target of the APC pathway | Q24310637 |
| Mechanical stretch up-regulates microRNA-26a and induces human airway smooth muscle hypertrophy by suppressing glycogen synthase kinase-3β | Q24610983 | ||
| miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis | Q24613599 | ||
| Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers | Q24625794 | ||
| Small C-terminal domain phosphatase enhances snail activity through dephosphorylation | Q24656011 | ||
| Oncomirs - microRNAs with a role in cancer | Q27860773 | ||
| Wnt/beta-catenin signaling in development and disease | Q27860784 | ||
| MicroRNA signatures in human cancers | Q27860962 | ||
| Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism | Q28114789 | ||
| Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors | Q28247928 | ||
| Causes and consequences of microRNA dysregulation in cancer | Q28258994 | ||
| PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs | Q28343682 | ||
| Myc deletion rescues Apc deficiency in the small intestine | Q28591197 | ||
| WNT and beta-catenin signalling: diseases and therapies | Q29616159 | ||
| Wnt signalling and its impact on development and cancer | Q29619273 | ||
| Cholangiocarcinoma: Current concepts and insights | Q33965702 | ||
| Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy | Q33984809 | ||
| Cholangiocarcinoma: modern advances in understanding a deadly old disease | Q34000079 | ||
| The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres | Q34075159 | ||
| Genetic variation in microRNA networks: the implications for cancer research | Q34177121 | ||
| Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. | Q34414026 | ||
| Wnt signaling: is the party in the nucleus? | Q34534188 | ||
| Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma | Q35362299 | ||
| FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma | Q35588892 | ||
| The epidemiology of cholangiocarcinoma | Q35802314 | ||
| The molecular pathogenesis of cholangiocarcinoma | Q35802318 | ||
| MicroRNA genes are frequently located near mouse cancer susceptibility loci | Q35808878 | ||
| Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma | Q36142292 | ||
| Wnt signalling: variety at the core. | Q36717707 | ||
| Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment | Q36900063 | ||
| Cholangiocarcinoma--controversies and challenges | Q37860916 | ||
| ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions | Q38455863 | ||
| Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. | Q40350197 | ||
| Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer | Q40420990 | ||
| Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation | Q40522774 | ||
| Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest | Q40588100 | ||
| Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells | Q40715147 | ||
| Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. | Q41298622 | ||
| Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells | Q41603441 | ||
| Chromosomal breakpoints in cholangiocarcinoma cell lines | Q41716300 | ||
| A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium | Q41961061 | ||
| Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids | Q46805111 | ||
| Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. | Q53354681 | ||
| Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. | Q53395387 | ||
| Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study | Q74428416 | ||
| Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma | Q74515216 | ||
| Cholangiocarcinoma | Q81735999 | ||
| MicroRNAs--the micro steering wheel of tumour metastases | Q83429939 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| microRNA | Q310899 | ||
| P304 | page(s) | 246-56.e8 | |
| P577 | publication date | 2012-04-03 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin | |
| P478 | volume | 143 |
| Q35562369 | A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma. |
| Q27005597 | Adeno-associated virus-mediated microRNA delivery and therapeutics |
| Q34174419 | An integrated analysis of the SOX2 microRNA response program in human pluripotent and nullipotent stem cell lines. |
| Q39259431 | Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders |
| Q52720960 | Animal models of cholangiocarcinoma. |
| Q64083820 | Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN-AKT axis |
| Q33709983 | Ceruloplasmin as a prognostic marker in patients with bile duct cancer. |
| Q36707594 | Characterizing the activation of the Wnt signaling pathway in hilar cholangiocarcinoma using a tissue microarray approach |
| Q26746000 | Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers |
| Q51747176 | Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator. |
| Q50420455 | Cohesive Regulation of Neural Progenitor Development by microRNA miR-26, Its Host Gene Ctdsp and Target Gene Emx2 in the Mouse Embryonic Cerebral Cortex. |
| Q93184511 | Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas |
| Q28073195 | Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers |
| Q26767120 | Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy |
| Q34200081 | Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma |
| Q38642455 | Emerging molecular targets and therapy for cholangiocarcinoma |
| Q47783721 | Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway |
| Q55406904 | Establishment and characterization of a GES-1 human gastric epithelial cell line stably expressing miR-23a. |
| Q38887635 | Expression of miRNA-26b in the diagnosis and prognosis of patients with non-small-cell lung cancer |
| Q64994192 | Extracellular Vesicles Derived from Hypoxic Human Mesenchymal Stem Cells Attenuate GSK3β Expression via miRNA-26a in an Ischemia-Reperfusion Injury Model. |
| Q100632902 | GATA6 promotes epithelial-mesenchymal transition and metastasis through MUC1/β-catenin pathway in cholangiocarcinoma |
| Q37631794 | Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells. |
| Q36733776 | Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia |
| Q41257594 | Integrated regulatory mechanisms of miRNAs and targeted genes involved in colorectal cancer |
| Q58560715 | Lentivirus‑mediated microRNA‑26a overexpression in bone mesenchymal stem cells facilitates bone regeneration in bone defects of calvaria in mice |
| Q89531772 | Long non-coding RNA NNT-AS1 promotes cholangiocarcinoma cells proliferation and epithelial-to-mesenchymal transition through down-regulating miR-203 |
| Q34982573 | Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. |
| Q38973071 | Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. |
| Q35742436 | MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. |
| Q36757035 | MiR-26a Rescues Bone Regeneration Deficiency of Mesenchymal Stem Cells Derived From Osteoporotic Mice |
| Q37046835 | MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2. |
| Q47104906 | MiR-26a contributes to the PDGF-BB-induced phenotypic switch of vascular smooth muscle cells by suppressing Smad1. |
| Q38706042 | MiR-26a downregulates retinoblastoma in colorectal cancer. |
| Q36080088 | MiR-26a enhances autophagy to protect against ethanol-induced acute liver injury. |
| Q38829769 | MiR-9-5p promotes MSC migration by activating β-catenin signaling pathway. |
| Q37213574 | MicroRNA 141 Expression Is a Potential Prognostic Marker of Biliary Tract Cancers |
| Q35028814 | MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule |
| Q34821676 | MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. |
| Q49790324 | MicroRNA-26a and Tumor |
| Q35032496 | MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma |
| Q41856145 | MicroRNA-26a inhibits osteosarcoma cell proliferation by targeting IGF-1. |
| Q35145305 | MicroRNA-26a inhibits proliferation by targeting high mobility group AT-hook 1 in breast cancer |
| Q35273569 | MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin |
| Q54094778 | MicroRNA-26a regulates ANXA1, rather than DAL-1, in the development of lung cancer. |
| Q36022340 | MicroRNA-26a supports mammalian axon regeneration in vivo by suppressing GSK3β expression |
| Q47616223 | MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway |
| Q36433424 | MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. |
| Q46255425 | MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway |
| Q42290877 | MicroRNA-26a targets MAPK6 to inhibit smooth muscle cell proliferation and vein graft neointimal hyperplasia |
| Q93185200 | MicroRNA-26a-5p inhibits proliferation, invasion and metastasis by repressing the expression of Wnt5a in papillary thyroid carcinoma |
| Q38714023 | MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines |
| Q26865762 | MicroRNAs and benign biliary tract diseases |
| Q33991899 | MicroRNAs in Cholangiopathies |
| Q36410357 | MicroRNAs in biliary diseases. |
| Q57460455 | MicroRNAs in the Migration of Mesenchymal Stem Cells |
| Q38217475 | Molecular mechanism of cholangiocarcinoma carcinogenesis |
| Q39120148 | Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets |
| Q48146413 | Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases. |
| Q37614231 | NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism. |
| Q47153848 | NcRNAs and Cholangiocarcinoma |
| Q38131056 | Novel diagnostic and prognostic biomarkers in biliary tract cancer. |
| Q35251736 | Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression |
| Q50130190 | Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin. |
| Q34656747 | Pathogenesis, diagnosis, and management of cholangiocarcinoma |
| Q47127377 | Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. |
| Q36095393 | Prognostic significance of microRNA-203 in cholangiocarcinoma |
| Q48214526 | Research and Development of Atractylodes lancea (Thunb) DC. as a Promising Candidate for Cholangiocarcinoma Chemotherapeutics |
| Q34825705 | Retracted: miR-26a and its Target CKS2 Modulate Cell Growth and Tumorigenesis of Papillary Thyroid Carcinoma |
| Q36210966 | Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma |
| Q98386355 | Small RNA profiles of HTLV-1 asymptomatic carriers with monoclonal and polyclonal rearrangement of the T-cell antigen receptor γ-chain using massively parallel sequencing: A pilot study |
| Q36766514 | TNF-α-induced NF-κB activation upregulates microRNA-150-3p and inhibits osteogenesis of mesenchymal stem cells by targeting β-catenin |
| Q92996083 | The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway |
| Q28076568 | The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer |
| Q64994278 | The role of miRNAs in cholangiocarcinoma. |
| Q38796729 | The role of microRNA-26a in human cancer progression and clinical application |
| Q26865749 | The significance of genetics for cholangiocarcinoma development |
| Q41146935 | Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers |
| Q39162380 | miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). |
| Q58604344 | miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease |
| Q39135735 | miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. |
| Q92761624 | miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2 |
| Q34981594 | miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer |
| Q38096240 | miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells |
| Q53099936 | miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. |
| Q38092617 | miRNA-Based Therapeutic Strategies |
| Q27011654 | microRNA regulation of Wnt signaling pathways in development and disease |
| Q64937042 | microRNA-196a promotes osteogenic differentiation and inhibit adipogenic differentiation of adipose stem cells via regulating β-catenin pathway. |
| Q35684366 | microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma. |
Search more.